Novartis Stock Forecast for 2023 - 2025 - 2030
Updated on 04/16/2024
Novartis Stock Forecast and Price Target
The average price target for Novartis's stock of CHF105.46 recently provided by nine leading analysts would represent a 21.92% upside from its last closing price if reached. This potential increase is based on a high estimate of CHF128.13 and a low estimate of CHF81.17. If you are not interested in NOVN stock, you may still be interested in its competitors and their current standings.
21.92% Upside
Novartis Fair Value Forecast for 2023 - 2025 - 2030
Novartis's Price has decreased by 100.00% In the last four years, from CHF77.68 to CHF0.00. For next year, analysts predict Fair Value of CHF97.04, which would mean an increase of 100.00%. Over the next seven years, experts predict that Novartis's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$750.77 | Buy/Sell | $636.99 | 11.55% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$161.67 | Buy/Sell | $178.42 | 17.38% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£110.24 | Buy/Sell | £165.99 | 47.53% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$108.89 | Buy/Sell | $118.92 | 17.55% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$265.51 | Buy/Sell | $303.65 | 20.33% |
Novartis Revenue Forecast for 2023 - 2025 - 2030
Novartis's Revenue has decreased by 6.49% In the last three years, from CHF49.90B to CHF46.66B. For next year, analysts predict Revenue of CHF47.74B, which would mean an increase of 2.31%. Over the next seven years, experts predict that Novartis's Revenue will grow at a rate of 8.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.51 | Buy/Sell | $58.15 | 13.38% |
| EL Stock Forecast | EssilorLuxottica Société ano... | Outperform |
12
|
203.80€ | Buy/Sell | 193.26€ | 0.59% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.55 | Buy/Sell | $205.51 | -27.07% |
.jpg)
Novartis Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Novartis's Dividend per Share has grown by 15.63%, rising from CHF3.39 to CHF3.92. The next year, 16 experts forecast that Novartis's Dividend per Share will decrease by 3.83%, reaching CHF3.77. Over the next seven years, experts predict that Novartis's Dividend per Share will grow at a rate of 2.70%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$234.72 | Buy/Sell | $284.47 | 19.29% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.56k | Buy/Sell | ¥5.24k | 27.17% |
| MMM Stock Forecast | 3M | Hold |
10
|
$91.30 | Buy/Sell | $109.39 | 9.53% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAS Stock Forecast | BASF | Outperform |
12
|
51.75€ | Buy/Sell | 49.50€ | 8.21% |
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF74.78 | Buy/Sell | CHF90.64 | 29.19% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$53.67 | Buy/Sell | $61.72 | 17.38% |
Novartis EBITDA Forecast for 2023 - 2025 - 2030
Novartis's EBITDA has grown In the last three years, rising from CHF16.97B to CHF17.52B – a growth of 3.25%. In the next year, analysts believe that EBITDA will reach CHF18.97B – an increase of 8.29%. For the next seven years, experts predict that Novartis's EBITDA will grow at a rate of 23.92%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DD Stock Forecast | DuPont de Nemours | Outperform |
17
|
$73.44 | Buy/Sell | $75.38 | 6.21% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$196.80 | Buy/Sell | $299.62 | 48.37% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.46€ | Buy/Sell | 45.15€ | 24.72% |
Novartis EBIT Forecast for 2023 - 2025 - 2030
Novartis's EBIT has seen impressive growth In the last three years, rising from CHF12.19B to CHF12.64B – a growth of 3.73%. In the next year, analysts believe that EBIT will reach CHF17.57B – an increase of 38.98%. For the next seven years, the forecast is for EBIT to grow by 46.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$101.58 | Buy/Sell | $96.90 | 4.06% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$147.70 | Buy/Sell | $245.24 | 45.57% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.45k | Buy/Sell | ¥2.64k | 45.23% |
Novartis EPS Price Prediction Forecast for 2023 - 2025 - 2030
Novartis's EPS has decreased by 100.00% In the last four years, from CHF5.78 to CHF0.00. For next year, analysts predict EPS of CHF7.22, which would mean an increase of 100.00%. Over the next seven years, experts predict that Novartis's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$91.51 | Buy/Sell | $111.56 | 18.78% |
| CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.38k | Buy/Sell | Rp1.43k | 7.21% |
| EXAS Stock Forecast | Exact Sciences | Buy |
8
|
$65.35 | Buy/Sell | $90.32 | 34.66% |
.jpg)